PMID- 2098504
OWN - NLM
STAT- MEDLINE
DCOM- 19910730
LR  - 20220318
IS  - 0390-5616 (Print)
IS  - 0390-5616 (Linking)
VI  - 34
IP  - 3-4
DP  - 1990 Jul-Dec
TI  - Lonidamine in the combined treatment of malignant gliomas. A randomized study.
PG  - 261-4
AB  - Lonidamine (LND) is a drug that interferes with energy metabolism of cancer 
      cells, principally inhibiting aerobic glycolytic activity, by its effect on 
      mitochondrially-bound hexokinase (HK). In such way LND could impair 
      energy-requiring processes, as recovery from potentially lethal damage, induced 
      by radiation treatment and by some cytotoxic drugs. A randomized study started in 
      November 1983, to evaluate the efficacy of LND in association with radiotherapy 
      as first line treatment in malignant gliomas, after surgical procedure. LND was 
      also used in association with Lomustine (CCNU) at the moment of documented 
      clinical and neuroradiological recurrence. At the present time 60 patients 
      entered the study, and 47 are evaluable. Present preliminary results are not 
      statistically significant, however indicate that LND tends to prolong the median 
      survival time and the rate of one year survivors.
FAU - Carapella, C M
AU  - Carapella CM
AD  - National Institute for Cancer Research, Regina Elena, Roma, Italy.
FAU - Paggi, M G
AU  - Paggi MG
FAU - Calvosa, F
AU  - Calvosa F
FAU - Cattani, F
AU  - Cattani F
FAU - Jandolo, B
AU  - Jandolo B
FAU - Mastrostefano, R
AU  - Mastrostefano R
FAU - Raus, L
AU  - Raus L
FAU - Riccio, A
AU  - Riccio A
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - Italy
TA  - J Neurosurg Sci
JT  - Journal of neurosurgical sciences
JID - 0432557
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Indazoles)
RN  - 7BRF0Z81KG (Lomustine)
RN  - U78804BIDR (lonidamine)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antineoplastic Agents/*therapeutic use
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - Brain Neoplasms/*drug therapy/radiotherapy/surgery
MH  - Combined Modality Therapy
MH  - Female
MH  - Glioma/*drug therapy/radiotherapy/surgery
MH  - Humans
MH  - Indazoles/*therapeutic use
MH  - Lomustine/administration & dosage
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Recurrence, Local/drug therapy
EDAT- 1990/07/01 00:00
MHDA- 1990/07/01 00:01
CRDT- 1990/07/01 00:00
PHST- 1990/07/01 00:00 [pubmed]
PHST- 1990/07/01 00:01 [medline]
PHST- 1990/07/01 00:00 [entrez]
PST - ppublish
SO  - J Neurosurg Sci. 1990 Jul-Dec;34(3-4):261-4.